TETRALITE is under clinical development by LiteVax and currently in Phase II for Seasonal Influenza. According to GlobalData, Phase II drugs for Seasonal Influenza have a 30% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how TETRALITE’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
TETRALITE overview
Tetralite is under development for the prevention of seasonal influenza. It is a novel, inactivated, adjuvanted influenza vaccine combining a low dose of a licensed vaccine with the novel, potent LiteVax adjuvant and administered through intramuscular route. The vaccine candidate is being developed based on LiteVax adjuvant technology which is based on a synthetic carbohydrate fatty acid monosulphate ester technology.
LiteVax overview
LiteVax is a biopharmaceutical company which focuses on development and exploitation of innovative vaccine adjuvant concepts for infectious diseases. LiteVax is headquartered in Oss, The Netherlands.
For a complete picture of TETRALITE’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
